0001209191-23-052139.txt : 20231005
0001209191-23-052139.hdr.sgml : 20231005
20231005072025
ACCESSION NUMBER: 0001209191-23-052139
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20230925
FILED AS OF DATE: 20231005
DATE AS OF CHANGE: 20231005
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Conway Vikki L
CENTRAL INDEX KEY: 0001995297
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-16174
FILM NUMBER: 231309807
MAIL ADDRESS:
STREET 1: C/O TEVA
STREET 2: 5 BASEL STREET, P.O. BOX 3190
CITY: PETACH TIKVA
STATE: L3
ZIP: 4951033
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TEVA PHARMACEUTICAL INDUSTRIES LTD
CENTRAL INDEX KEY: 0000818686
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5 BAZEL ST
STREET 2: P O B 3190
CITY: PETACH TIKVA
STATE: L3
ZIP: 49131
BUSINESS PHONE: 9729267267
MAIL ADDRESS:
STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED
STREET 2: 5 BAZEL ST PO B 3190
CITY: PETACH TIKVA
STATE: L3
ZIP: 49131
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2023-09-25
0
0000818686
TEVA PHARMACEUTICAL INDUSTRIES LTD
TEVA
0001995297
Conway Vikki L
C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.
124 DVORA HANEVI'A STREET
TEL AVIV
L3
ISRAEL
0
1
0
0
See "Remarks"
Stock Options (right to buy)
48.76
2024-03-12
Ordinary Shares
2268
D
Stock Options (right to buy)
60.21
2025-03-12
Ordinary Shares
3504
D
Stock Options (right to buy)
53.50
2026-03-17
Ordinary Shares
8003
D
Stock Options (right to buy)
34.70
2027-03-03
Ordinary Shares
15003
D
Stock Options (right to buy)
16.99
2027-09-18
Ordinary Shares
4571
D
Stock Options (right to buy)
19.16
2028-03-02
Ordinary Shares
25003
D
Restricted Share Units
Ordinary Shares
4294
D
Restricted Share Units
Ordinary Shares
9911
D
Restricted Share Units
Ordinary Shares
21354
D
Restricted Share Units
Ordinary Shares
20717
D
Stock options were granted on March 12, 2014, with 1,134 having vested on each of March 12, 2016 and March 12, 2017.
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Stock options were granted on March 12, 2015, with 876 having vested on each of March 12, 2016, March 12, 2017, March 12, 2018, and March 12, 2019.
Stock options were granted on March 17, 2016, with 2,000 having vested on each of March 17, 2017, March 17, 2018 and March 12, 2019, and 2,003 having vested on March 17, 2020.
Stock options were granted on March 3, 2017, with 3,750 having vested on each of March 3, 2018, March 3, 2019 and March 3, 2020, and 3,753 having vested on March 3, 2021.
Stock options were granted on September 18, 2017, with 4,571 having vested on September 18, 2019.
Stock options were granted on March 2, 2018, with 6,250 having vested on each of March 2, 2019, March 2, 2020 and March 2, 2021, and 6,253 having vested on March 2, 2022.
Restricted share units were granted on February 28, 2020, with 4,294 vesting on February 28, 2024.
Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources
and Compensation Committee, the cash value of one ordinary share.
Restricted share units were granted on March 5, 2021, with 4,954 vesting on March 5, 2024, and 4,957 vesting on March 5, 2025.
Restricted share units were granted on March 4, 2022, with 7,117 vesting on each of March 4, 2024 and March 4, 2025, and 7,120 vesting on March 4, 2026.
Restricted share units were granted on March 3, 2023, with 5,179 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 5,180 vesting on March 3, 2027.
Exhibit 24 - Power of Attorney.
Acting Head of Global Human Resources.
/s/ Dov Bergwerk, as attorney-in-fact for Vikki L. Conway
2023-10-05
EX-24
2
poa.txt
POA DOCUMENT
Exhibit 24
POWER OF ATTORNEY
FOR SECTION 16 REPORTING OBLIGATIONS
KNOW ALL BY THESE PRESENTS, that the undersigned hereby makes, constitutes and
appoints Dov Bergwerk, Shira Aran-Porat and Matan Kimchi signing singly, as the
undersigned's true and lawful attorney-in-fact, with full power and authority as
hereinafter described on behalf of and in the name, place and stead of the
undersigned to:
(1) prepare, execute, acknowledge, deliver and file Forms 3, 4, and 5 (including
any amendments thereto) with respect to the securities of Teva Pharmaceutical
Industries Limited, a company incorporated under the law of Israel, or any
successor thereto (the "Company"), with the U.S. Securities and Exchange
Commission, any national securities exchanges and the Company, as considered
necessary or advisable under Section 16(a) of the Securities Exchange Act of
1934 and the rules and regulations promulgated thereunder, as amended from time
to time (the "Exchange Act");
(2) seek or obtain, as the undersigned's representative and on the undersigned's
behalf, information of transactions in the Company's securities from any
third-party, including brokers, employee benefit plan administrators and
trustees, and the undersigned hereby authorizes any such person to release any
such information to the undersigned and approves and ratifies any such release
of information; and
(3) perform any and all other acts which in the discretion of such
attorney-in-fact is necessary or desirable for and on behalf of the undersigned
in connection with the foregoing.
The undersigned acknowledges that:
(1) this Power of Attorney authorizes, but does not require, such
attorney-in-fact to act in his or her discretion on information provided to such
attorney-in-fact without independent verification of such information;
(2) any documents prepared, executed, acknowledged and/or delivered by such
attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney
will be in such form and will contain such information and disclosure as such
attorney-in-fact, in his or her discretion, deems necessary or desirable;
(3) neither the Company nor such attorney-in-fact assumes (i) any liability for
the undersigned's responsibility to comply with the requirement of the Exchange
Act, (ii) any liability of the undersigned for any failure to comply with such
requirements or (iii) any obligation or liability of the undersigned for profit
disgorgement under Section 16(b) of the Exchange Act; and
(4) this Power of Attorney does not relieve the undersigned from responsibility
for compliance with the undersigned's obligations under the Exchange Act,
including without limitation the reporting requirements under Section 16 of the
Exchange Act.
The undersigned hereby gives and grants the foregoing attorney-in-fact full
power and authority to do and perform all and every act and thing whatsoever
requisite, necessary or appropriate to be done in and about the foregoing
matters as fully to all intents and purposes as the undersigned might or could
do if present, hereby ratifying all that such attorney-in-fact of, for and on
behalf of the undersigned, shall lawfully do or cause to be done by virtue of
this Power of Attorney.
This Power of Attorney shall remain in full force and effect until revoked by
the undersigned in a signed writing delivered to such attorney-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 26th day of September, 2023.
By: /s/ Vikki L. Conway
Name: Vikki L. Conway
Title: Acting Executive Vice President, Global Head of HR